[O-04] Oral Session 04　Neuromuscular junction disease 1 | 66th Annual Meeting of the Japanese Society of Neurology

Advanced Search

Session Details

Oral Session

[O-04]Oral Session 04　Neuromuscular junction disease 1

Wed. May 21, 2025 3:35 PM - 5:05 PM JST
Wed. May 21, 2025 6:35 AM - 8:05 AM UTC

第06会場(大阪国際会議場10F 会議室1008)

Chair: Naoki Kawaguchi（Neurological center, Neurology Chiba Clinic, Japan）

[O-04-1]Clinical Significance of Serial Antibody Titers in MuSK antibody-positive Myasthenia Gravis

Manato Yasuda¹, Akiyuki Uzawa¹, Hiroyuki Akamine¹, Etsuko Ogaya¹, Hideo Handa¹, Kentaro Kurumada¹, Yukiko Ozawa^1,2, Satoshi Kuwabara¹ (1.Department of Neurology, Graduate School of Medicine, Chiba University, Japan, 2.Department of Neurology, Japanese Narita Red Cross Hospital, Japan)

[O-04-2]Lambert-Eaton myasthenia syndrome associated with immune checkpoint inhibitor

Hiroki Maesaka¹, Yosuke Eguchi², Shungo Imai³, Masakatsu Motomura⁴, Shigeaki Suzuki⁵, Shunya Nakane¹, Yuji Nakatsuji¹ (1.Department of Neurology, Faculty of Medicine, University of Toyama, Japan, 2.Respiratory Medicine, Bellland General Hospital, Japan, 3.Division of Drug Informatics, Faculty of Pharmacy, Keio University, Japan, 4.Medical Engeneering Course, Nagasaki Institute of Applied Science, Japan, 5.Department of Neurology, Keio University School of Medicine, Japan)

[O-04-3]Healthcare Economic Analysis of C5 Inhibitors for Generalized Myasthenia Gravis in Japan

Mieko Ogino¹, Akiyuki Uzawa², Koichi Shiraishi³, Eiko Yamamura³, Kazuhiko Tawara³, Kentaro Taki⁴, Kunihiko Shiraiwa⁴, Yohei Ohashi⁴ (1.International University of Health and Welfare School of Medicine Center for Medical Education, Japan, 2.Department of Neurology, Graduate School of Medicine, Chiba University, Japan, 3.Access, Sustainability & External Engagement, UCB, Japan, 4.Medical Affairs Rare Disease, Medical Affairs Japan, UCB, Japan)

[O-04-4]Safety and Effectiveness of Efgartigimod in Patients with gMG in Japan: Interim Analysis of PMS Data

Hirofumi Teranishi¹, Koichi Tsuda¹, Rumiko Kanzaki², Tomoyo Hayashi², Daisuke Harada¹ (1.argenx Japan K.K. Medical Affairs, Japan, 2.argenx Japan K.K. Global Patient Safety, Japan)

[O-04-5]the transition to the subcutaneous injection of the FcRn inhibitor for generalized myasthenia gravis

Masaaki Yoshikawa¹, Yuta Goto¹, Takeru Kawanami¹, Koya Tanaka², Keisuke Tsumura¹, Yuki Hoshino¹, Toshihiro Ide¹, Chika Shichijo¹, Kohei Suzuyama¹, Megumi Iwasaki³, Makoto Eriguchi², Motohiro Yukitake⁴, Hiroshi Takashima², Haruki Koike¹ (1.Division of Neurology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan, 2.Department of Neurology, Saga-Ken Medical Centre Koseikan, Japan, 3.Department of Neurology, Karatsu Red Cross Hospital, Japan, 4.Department of Neurology, Kouhoukai Takagi Hospital, Japan)

[O-04-6]Self-administration of rozanolixizumab in generalized myasthenia gravis: MG0020 study

Genya Watanabe^1,11, Carlo Antozzi^2,11, Tomasz Berkowicz^3,11, Vera Bril^4,11, Artur Druzdz^5,11, Rachana K. Gandhi Mehta^6,11, Zabeen K. Mahuwala^7,11, Jana Zschüntzsch^8,11, Marion Boehnlein⁹, Andreea Lavrov⁹, Mark Morris⁹, Puneet Singh⁹, M. Isabel Leite^10,11, MG0020 study team¹¹ (1.Department of Neurology, National Hospital Organization Sendai Medical Center, Japan, 2.Neuroimmunology and Muscle Pathology Unit, Multiple Sclerosis Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Neurologico Carlo Besta, Italy, 3.Miejskie Centrum Medyczne JONSCHER, Poland, 4.University Health Network, Toronto, Canada, 5.Department of Neurology, Municipal Hospital, Poland, 6.Department of Neurology, Wake Forest University School of Medicine, USA, 7.Department of Neuromuscular Medicine, Epilepsy and Clinical Neurophysiology, University of Kentucky, USA, 8.Department of Neurology, University Medical Center Göttingen, Germany, 9.UCB, Other country, 10.Nuffield Department of Clinical Neurosciences, University of Oxford, UK, 11.MG0020 study team)

Back to Category List